Proove Biosciences Continues to Present Leading Pain Genetics Research at American Academy of Pain Management's Annual Meeting

Researchers at Proove Biosciences Reveal Findings for Genetic Variability in Pain Patients and Clinical Utility for Genetic Testing

(PRWEB) February 19, 2016

Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, presented findings on the link between genetics and pain at the American Academy of Pain Management's (AAPM) 32nd Annual Meeting. As the only company presenting clinical data for the fourth consecutive year at the conference, Proove Biosciences provided new insights that might lead to better patient care. The three presentations focused identifying genetic variants of different types of pain patients, confirming the link between specific genes and fibromyalgia, and assessing the clinical utility of genetic testing.

In a study with 1,512 patients, the team discovered that genetic variants associated with pain pathways and drug metabolism might differ among patients suffering from nociceptive pain and neuropathic pain, respectively. By understanding these genetic differences, doctors might be able to tailor treatment plans based on the source of the pain. With the second study, researchers evaluated 128 genes in 108 patients who were diagnosed with fibromyalgia. The study identified eight genes that were associated with an increased risk of fibromyalgia. "We're excited that our internal research continues to build upon new discoveries in genetic testing and personalized care," said Brian Meshkin, CEO at Proove Biosciences.

In the third study, the team assessed clinical utility for 600 patients in 13 clinics across the United States. Among the physicians who ordered genetic testing, 80% reported that it benefited patient care, 38% reported a change in the type of drug used or dosing levels, and 36.5% revealed a reduction in the number of medications used in trial-and-error. "We are committed to reducing the reliance on trial-and-error prescribing," continued Meshkin. "With continued research, we are confident that physicians will have enough information to create customized treatment plans for every patient."

About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/02/prweb13226230.htm